Bioherb - Multiple Myeloma
Multiple Myeloma: Is a plasma cell Cancer in which a clone of malignant plasma cell or myeloma cell forms Tumor in the bone marrow that may cause disruption of normal function of the bone marrow, invasion and destruction of the normal bone structure, decrease in normal immune function and production of large quantity of abnormal antibodies that can be measured in the blood sample through laboratory test as Monoclonal Band. Since 1845 when the first patient was diagnosed in London, many treatment protocol have been tried or still being used but there is no easy cure for it.
Recovery of a last stage Multiple Myeloma type of Cancer with our Cancer Treatment Program.
Chemotherapy (Cyclophosphamide), Plasmaphoresis and Radiation therapies failed and in May 2003, the patient was told that he had a very short time to live and that there was no further treatment for him. He took Dr. Toora's cancer treatment for seven months. He is currently alive and in good health.
Clinical tests were monitored by the Oncologist every 3 months.
Patient before and after taking six months of treatment (above).
Clinical recovery data of the patient:
( ) indicates normal range
Monoclonal band is a form of protein produced by the cancerous cells and monitored in the blood as a marker to determine Cancer activity.
Note: In May 2003 patient was told that he hardly has a month to live. After our treatment there are 8 blood reports indicating zero Monoclonal band. This patient is currently alive and healthy. According to experts people with this form of Cancer can hardly live beyond 36 months from the time of diagnosis.
Liver Enzymes, Alk. Phos., GGT, AST and LD are within normal range after our treatment which indicates that there is no liver damage and our treatment is very safe.
Comparison study of Multiple Myeloma recovery treated with Dexamethasone, Pamidronat and our Cancer Treatment Program prior to Autologous Stem Cell Transplant and Malphalan treated post - Stem Cell Transplant
( ) indicates normal range * % reduction
CT Scan (skeletal survey Feb. 09):Progression of the disease, compression of T8 vertebral body. Evidence of lytic lesions involving L3 either new or advanced. Suggestion of a faint lytic lesion involving the right greater trochanteric region on the right side
CT Scan (Lumbar Spine Mar. 09): Lytic lesion in the S1. Numerous widespread tiny lytic foci are seen through all visualized bones, lytic lesions present in both medial iliac ala larger on the left (2.4 cm).
Note: The M protein reduced by 75.4 % with our treatment and dexamethasone prior to stem cell treatment but the doctors went ahead with stem cell transplant. 8 months later though there was reduction in the M protein but there was an increase in Mar. 09 and CT scan indicated the progression of the Cancer. The patient was put on Revlimid (palliative) in Mar. 09 and Re-started our treatment in June 09. By July 09 there was a drastic decrease in M protein, and since then, until now (2019), there has been no need for our treatment.
Liver Enzymes, ALT and AST (Transaminase) are within normal range after our treatment which indicates that there is no liver damage and our treatment is very safe even when combined with other anti-Cancer drug.
Recovery of a 77 years old male patient with Multiple Myeloma type of Cancer with our Cancer Treatment Program
Due to age factor and already 50% reduction in kidney filtration rate (eGFR), patient was not given any other treatment
Patient is only on our treatment since May 2008. Clinical tests were monitored by the Oncologist every 3 months.
( ) indicates normal range
Note: Due to 50% reduction in kidney function (see eGFR only 27) and age factor, patient was not given any other form of treatment.
With a great initial recovery in Aug-Nov. 08 patient stopped our products for 2 months and there was an increase in M protein, total protein, gamma globulin and alpha globulin and a decrease in Hgb, RBC and eGFR. Patient re-started our treatment and is currently on our treatment with great health.
Liver Enzymes, AST, GGT, and LD are within normal range during 16 months of taking our treatment which indicates that there is no liver damage and our treatment is very safe.
Page last updated: July 2019
